Cited by 218SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 29 of the 34 references it cites were found in a registry or an index, and 2 are not checked yet.

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Open access

Wang, Kai, Long, Quan-Xin, Deng, Hai-Jun, Hu, Jie, Gao, Qing-Zhu, Zhang, Gui-Ji, He, Chang-Long, Huang, Lu-Yi, Hu, Jie-Li, Chen, Juan, Tang, Ni, Huang, Ai-Long·2021·Clinical Infectious Diseases

DOI 10.1093/cid/ciaa1143PMC PMC7454328

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific neutralizing antibodies (NAbs) in patients with COVID-19. Methods: Blood samples (n = 173) were collected from 30 patients with COVID-19 over a 3-month period after symptom onset and analyzed for SARS-CoV-2–specific NAbs using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines. Results: SARS-CoV-2–specific NAb titers were low for the first 7–10 days after symptom onset and increased after 2–3 weeks. The median peak time for NAbs was 33 days (interquartile range [IQR], 24–59 days) after symptom onset. NAb titers in 93.3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34.8% (IQR, 19.6–42.4%). NAb titers increased over time in parallel with the rise in immunoglobulin G (IgG) antibody levels, correlating well at week 3 (r = 0.41, P < .05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including stem cell factor (SCF), TNF-related apoptosis-inducing ligand (TRAIL), and macrophage colony-stimulating factor (M-CSF). Conclusions: These data provide useful information regarding dynamic changes in NAbs in patients with COVID-19 during the acute and convalescent phases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa1143

Cites

29 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Analysis of the plasma response to SARS-CoV-2 infection. A, Sera from 5 convalescent patients with COVID-19 neutralized the SARS-CoV-2 pseudovirus. A serum sample from a healthy individual served as the negative control. The assay was performed in triplicate, and the median percentage of neutralization is shown. B, SARS-CoV-2 NAb titers of 20 plasma samples from convalescent patients with COVID-19 and 10 plasma samples from healthy donors. C, NAbs against VSVG, SARS-CoV, and SARS-CoV-2 pseudovirus in the sera from 30 convalescent patients with COVID-19. Abbreviations: COVID-19, coronavirus disease 2019; F, female; ID50, 50% inhibitory dose; M, male; NAb, neutralizing antibody; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VSVG, vesicular stomatitis virus G.CC BY-NC-ND · PubMed Central

Figure 2. Dynamic changes in NAbs against SARS-CoV-2. A, Kinetics of SARS-CoV-2 NAb levels in 30 patients with COVID-19. B, Number of patients experiencing peak NAb levels during hospitalization or after discharge. Follow-up point 1 represents the follow-up study conducted on 2 April while follow-up point 2 represents the follow-up study conducted on 8 May 2020. C, Peak NAb levels in the patients. D, Comparison of peak NAb levels between patients with COVID-19 experiencing peak NAb levels during hospitalization and patients with COVID-19 experiencing peak NAb levels after discharge. Abbreviations: COVID-19, coronavirus disease 2019; F, female; ID50, 50% inhibitory dose; M, male; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.CC BY-NC-ND · PubMed Central

Figure 3. Decrease in NAb levels in patients with COVID-19. A, Comparison of NAb levels between the peak point and the follow-up time point 2. B, Percentage decrease in NAbs in patients with COVID-19. Abbreviations: COVID-19, coronavirus disease 2019; ID50, 50% inhibitory dose; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.CC BY-NC-ND · PubMed Central

Figure 4. Correlation between the dynamics of NAb and virus-specific IgG levels. A, Kinetics of NAb and IgG levels in 6 patients. Plasma samples were collected at different time points after symptom onset. B, A total of 152 serum samples were grouped by time of collection after symptom onset; correlations were analyzed between NAb levels and IgG levels in each group. C, Correlations between NAb levels and IgG levels from serum samples collected 3 weeks after symptom onset. Abbreviations: F, female; ID50, 50% inhibitory dose; IgG, immunoglobulin G; M, male; NAb, neutralizing antibody.CC BY-NC-ND · PubMed Central

Figure 5. A–C, Correlation between peak NAb levels and cytokines in sera. Serum samples with the highest NAb levels for all individuals were collected during hospitalization. Cytokine or levels were measured using the Bio-Plex Human Cytokine Screening Panel (48-Plex no. 12007283; Bio-Rad) on a Luminex 200 (Luminex Multiplexing Instrument, Merck Millipore), following the manufacturer’s instructions. Pearson’s correlation was used to analyze differences between NAb levels and cytokine levels. Abbreviations: ID50, 50% inhibitory dose; M-CSF, macrophage colony-stimulating factor; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SCF, stem cell factor; TRAIL, tumor necrosis factor (TNF)–related apoptosis-inducing ligand.CC BY-NC-ND · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Self-citation
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Self-citation
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,298
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,968
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes
Connor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology · doi:10.1006/viro.1995.1016 · Cited by 1,253
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038

Show all 34 references

Research works printed but not linked: 1

Luchsinger, 2020, Serological analysis of New York City COVID19 convalescent plasma donors, medRxiv

Sorted by citations

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Viral targets for vaccines against COVID-19
Dai, L., & Gao, G. F. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 1,056
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., Hansen, L., Haile, A., Klebert, M. K., Pusic, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03647-4 · Cited by 532

See all 218

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265
Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study
Xu, X. P., Nie, S., Wang, Y., Long, Q., Zhu, H., Zhang, X., Sun, J., Zeng, Q., Zhao, J., Liu, L., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00611-6 · Cited by 28
Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19.
Li, L. H., Tu, H. W., Liang, D., Wen, C. Y., Li, A. A., Lin, W. Y., Hu, K. Q., Hong, W. S., Li, Y. P., Su, J., et al. (2021) · PubMed Central · doi:10.3967/bes2021.133 · Cited by 1
The changing dynamics of neutralizing antibody response within 10 months of SARS‐CoV‐2 infections
Baştuğ, A., Bodur, H., Aydos, Ö., Filazi, N., Öksüz, E., & Özkul, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27544 · Cited by 2
SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
Vacharathit, V., Srichatrapimuk, S., Manopwisedjaroen, S., Kirdlarp, S., Srisaowakarn, C., Setthaudom, C., Inrueangsri, N., Pisitkun, P., Kunakorn, M., Hongeng, S., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.021 · Cited by 22
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
Jeewandara, C., Jayathilaka, D., Gomes, L., Wijewickrama, A., Narangoda, E., Idampitiya, D., Guruge, D., Wijayamuni, R., Manilgama, S. R., Ogg, G. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81629-2 · Cited by 51
Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients
Chansaenroj, J., Yorsaeng, R., Puenpa, J., Wanlapakorn, N., Chirathaworn, C., Sudhinaraset, N., Sripramote, M., Chalongviriyalert, P., Jirajariyavej, S., Kiatpanabhikul, P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267102 · Cited by 38
Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
Yamayoshi, S., Yasuhara, A., Ito, M., Akasaka, O., Nakamura, M., Nakachi, I., Koga, M., Mitamura, K., Yagi, K., Maeda, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100734 · Cited by 151
Changes in Serum Neutralizing Antibodies Levels During Convalescence of COVID-19 Patients
Chen, Q., Gong, L., Wu, X., Feng, Y.-T., Luo, W.-R., Zhou, X., Yuan, Y., Yu, J., He, L., Wang, P., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.829273
Longitudinal Analysis of Virus Load, Serum Antibody Levels and Virus Neutralizing Activity In Vitro in Cases with Less Severe COVID-19Preprint
Flehmig, B., Schindler, M., Ruétalo, N., Businger, R., Bayer, M., Haage, A., Kirchner, T., Klingel, K., Normann, A., Pridzun, L., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3666854 · Cited by 1

Authors: Wang, K., Long, Q.-X., Deng, H.-J., Hu, J., Gao, Q.-Z., Zhang, G.-J., He, C.-L., Huang, L.-Y., Hu, J.-L., Chen, J., Tang, N., & Huang, A.-L.
Affiliations: Second Affiliated Hospital of Chongqing Medical University (CN)
Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Corresponding author: Huang, Ai-Long
ORCID: Wang, Kai
Hu, Jie
Chen, Juan
Tang, Ni
Huang, Ai-Long
Venue: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2020-08-03
Volume: 73
Issue: 3
Pages: e531-e539
ISSN: 1058-4838 (ISSN-L)
1537-6591
DOI: 10.1093/cid/ciaa1143
PMC: PMC7454328
OpenAlex: W3046309975
Cited by: 218
References: 34
Citations by year: 2026: 1 · 2025: 8 · 2024: 15 · 2023: 26 · 2022: 37 · 2021: 101 · 2020: 30
FWCI: 6.36
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Science and Technology Commission of Chongqing (cstc2020jscx-fyzx0053)
Chongqing Medical University (CQMUNCP0302, CQMUNCP0304)
Leading Talent Program of Chongqing Science and Technology Commission (CSTCCXLJRC201719)
Major National Science and Technology Program (2017ZX10202203)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, antibody kinetics, IgG, inflammatory cytokines, stem cell factor, TRAIL, macrophage colony-stimulating factor, convalescence
MeSH terms: COVID-19, SARS-CoV-2, Antibodies, Viral, Humans, Antibodies, Neutralizing, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks